As a bridge to transplant, the HeartMate II is showing excellent survival, good recovery potential for the heart, kidneys and liver, and a favorable impact on quality of life, says Francis Pagani, M.D., Ph.D., co-lead author of the new paper and the director of the U-M Cardiovascular Centers Center for Circulatory Support. These results suggest it would be a very good addition to the options that physicians have for treating patients who require ventricular assistance while they wait for a new heart, and that it has the potential to last years rather than months.
Pagani is an associate professor of cardiac surgery at the U-M Medical School and has led U-Ms participation in numerous clinical trials of heart-assisting devices, including the trials of the original HeartMate device and the pilot HeartMate II trial that preceded the large trial whose results are reported today.
His co-lead author on the paper is Leslie Miller, M.D., a noted cardiologist formerly at the University of Minnesota who is now the director of cardiology programs at Washington Hospital Center.
Currently, according to the United Network for Organ Sharing, adults who need a heart transplant wait an average of 170 days, but nearly 30 percent are still waiting even after two years on the transplant list. As of August 24, 2,640 Americans of all ages are waiting for a heart transplant.
The new study included 133 patients, and assessed the devices ability to support patients for six months, or until they received a transplant or recovered heart function, whichever came first.
The researchers assessed patients functional heart status, as measured by t
|Contact: Kara Gavin|
University of Michigan Health System